FDA issues guidance to increase the availability of NARCAN

Photo of NARCAN

The FDA has issued new guidance to expand availability and access to naloxone for harm reduction programs. The guidance clarifies a public health emergency exclusion and exemption from requirements of the Drug Supply Chain Security Act (DSCSA) regarding the distribution of FDA-approved naloxone products to harm reduction programs.